Xiaohui Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xiaohui Wang has a total of 101 co-authors. Here are the top co-authors by number of shared publications:
Li Wang
Key Laboratory of Cellular Physiology, Ministry of Education, Shanxi Medical University, Taiyuan, China
10 shared publications- Li Wang
Department of Pathology, Shanxi Medical University, Taiyuan, Shanxi, China
5 shared publications Kaili Du
Department of Pathology School of Basic Medical Science Shanxi Medical University 030001 Taiyuan China
4 shared publicationsXiuya Zhou
Department of Pathology West China Hospital West China
4 shared publicationsYang Li
Department of Pathology School of Basic Medical Science, Shanxi Medical University Taiyuan Shanxi People's Republic of China
4 shared publicationsCong Sun
Basic Medical Sciences Center Shanxi Medical University Taiyuan China
3 shared publications
Latest Publications
- Open Access
- 25 September 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (18) , e71379
Identification of a Lactylation‐Related Gene Signature and Candidate Biomarkers for Dilated Cardiomyopathy
Dilated cardiomyopathy (DCM) is a leading cause of heart failure. Due to its complex pathogenesis, effective treatment strategies remain limited. Therefore, it is particularly important to identify novel candidate biomarkers from the pathogenesis level. In recent years, lactylation modification plays an important role in various cardiovascular diseases; however, its specific involvement in DCM remains unclear. Therefore, it is of great significance to identify lactylation‐related biomarkers associated with DCM to provide insights for future mechanistic investigations. The DCM gene expression datasets were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes and co‐expression modules were identified using differential expression analysis and weighted gene co‐expression network analysis (WGCNA). Lactylation‐related gene sets (LRGs) were obtained from the MSigDB database. The intersection of these results was further analysed using machine learning algorithms: Least Absolute Shrinkage and Selection Operator (LASSO), Random Forest (RF), and Support Vector Machine (SVM). CIBERSORT algorithm was used to analyse the immune infiltration characteristics of DCM, and DCM was divided into two subtypes by unsupervised consensus clustering. Mendelian randomization (MR) analysis was employed to evaluate potential causal associations between the candidate genes and DCM or heart failure progression. Finally, the candidate genes were verified by the GSE57338 database and β 1 ‐AA‐induced heart failure model with DCM characteristics. Through comprehensive transcriptomic analysis integrating WGCNA and LRGs, 38 characteristic genes associated with DCM and lactylation were finally identified. Subsequently, 18 key genes were selected by machine learning. The risk prediction model based on these genes demonstrated good predictive performance for DCM. Immune infiltration analysis revealed dysregulated inflammatory responses in DCM patients, and 18 key genes were significantly related to CD8 + T cells, CD4 + T cells, neutrophils, and Natural killer T cell infiltration. Unsupervised consensus clustering divided DCM patients into two distinct subtypes (C1 and C2), with marked differences in gene expression. Subtype C1 was characterized by activation of CD8 + T cells and Natural Killer T cells, whereas C2 mainly exhibited CD4 + T cells and neutrophils activation. Furthermore, Mendelian randomization analysis suggested that EXT1 may be associated with heart failure, while IER3 was potentially associated with DCM. Finally, the external validation set GSE57338 and the heart failure model with DCM characteristics were used to verify the two genes identified. The results showed that EXT1 was up‐regulated and IER3 was down‐regulated. Based on the deep excavation of public database, combined with machine learning algorithm and Mendelian randomization, this study identified EXT1 and IER3 as potential candidate biomarkers for DCM, providing a new theoretical foundation and hypotheses for future mechanistic and translational research.
- 25 September 2026
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 30 (18) , e71379
Open AccessIdentification of a Lactylation‐Related Gene Signature and Candidate Biomarkers for Dilated Cardiomyopathy
Dilated cardiomyopathy (DCM) is a leading cause of heart failure. Due to its complex pathogenesis, effective treatment strategies remain limited. Therefore, it is particularly important to identify novel candidate biomarkers from the pathogenesis level. In recent years, lactylation modification plays an important role in various cardiovascular diseases; however, its specific involvement in DCM remains unclear. Therefore, it is of great significance to identify lactylation‐related biomarkers associated with DCM to provide insights for future mechanistic investigations. The DCM gene expression datasets were obtained from the Gene Expression Omnibus (GEO) database. Differentially expressed genes and co‐expression modules were identified using differential expression analysis and weighted gene co‐expression network analysis (WGCNA). Lactylation‐related gene sets (LRGs) were obtained from the MSigDB database. The intersection of these results was further analysed using machine learning algorithms: Least Absolute Shrinkage and Selection Operator (LASSO), Random Forest (RF), and Support Vector Machine (SVM). CIBERSORT algorithm was used to analyse the immune infiltration characteristics of DCM, and DCM was divided into two subtypes by unsupervised consensus clustering. Mendelian randomization (MR) analysis was employed to evaluate potential causal associations between the candidate genes and DCM or heart failure progression. Finally, the candidate genes were verified by the GSE57338 database and β 1 ‐AA‐induced heart failure model with DCM characteristics. Through comprehensive transcriptomic analysis integrating WGCNA and LRGs, 38 characteristic genes associated with DCM and lactylation were finally identified. Subsequently, 18 key genes were selected by machine learning. The risk prediction model based on these genes demonstrated good predictive performance for DCM. Immune infiltration analysis revealed dysregulated inflammatory responses in DCM patients, and 18 key genes were significantly related to CD8 + T cells, CD4 + T cells, neutrophils, and Natural killer T cell infiltration. Unsupervised consensus clustering divided DCM patients into two distinct subtypes (C1 and C2), with marked differences in gene expression. Subtype C1 was characterized by activation of CD8 + T cells and Natural Killer T cells, whereas C2 mainly exhibited CD4 + T cells and neutrophils activation. Furthermore, Mendelian randomization analysis suggested that EXT1 may be associated with heart failure, while IER3 was potentially associated with DCM. Finally, the external validation set GSE57338 and the heart failure model with DCM characteristics were used to verify the two genes identified. The results showed that EXT1 was up‐regulated and IER3 was down‐regulated. Based on the deep excavation of public database, combined with machine learning algorithm and Mendelian randomization, this study identified EXT1 and IER3 as potential candidate biomarkers for DCM, providing a new theoretical foundation and hypotheses for future mechanistic and translational research.
- 19 September 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- p. 1-18
Genetically supported targets and drug repurposing for sleep disorders: a Mendelian randomization systematic study
Sleep disorders present major public health issues because of their associations with chronic diseases. Despite extensive research efforts, the underlying biological mechanisms remain inadequately understood. We performed bidirectional two-sample Mendelian randomization (MR) to investigate relationships between sleep disorders and common brain diseases, followed by summary-data-based Mendelian randomization (SMR), heterogeneity in dependent instruments (HEIDI), and colocalization analyses integrating protein quantitative trait locus (pQTL) and expression quantitative trait locus (eQTL) data to prioritize genetically supported candidate genes. Compound-gene associations were subsequently evaluated, and selected clinically used compounds underwent exploratory molecular docking and molecular dynamics simulation. Two-step MR mediation analyses and MR phenome-wide association study (MR-PheWAS) were used to investigate potential mediating traits and broader phenotypic associations. Multi-omic genetic analyses prioritized six candidate genes—BCAN, HDGF, MEPE, PAM, PRR4, and IGLON5—with BCAN, HDGF, and MEPE showing the strongest genetic support. Compound prioritization retained four clinically used drugs associated with the candidate genes for structure-based assessment. Exploratory molecular docking yielded the most favorable predicted Vina score for the BCAN–danazol pair, and molecular dynamics simulation showed persistent local BCAN–danazol contacts despite substantial global conformational rearrangement of BCAN during the trajectory. Mediation analyses identified several risk factors, cerebrospinal fluid metabolites, and structural connectivity measures showing statistical evidence consistent with partial mediation of selected gene/protein–sleep disorder associations. MR-PheWAS further characterized broader phenotypic associations of the genetically supported genes. Integrating genetic and multi-omic evidence identified candidate molecular targets and compound-gene associations relevant to sleep disorders. These findings provide hypotheses for subsequent functional and pharmacological validation.
- 19 September 2026
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- p. 1-18
Genetically supported targets and drug repurposing for sleep disorders: a Mendelian randomization systematic study
Sleep disorders present major public health issues because of their associations with chronic diseases. Despite extensive research efforts, the underlying biological mechanisms remain inadequately understood. We performed bidirectional two-sample Mendelian randomization (MR) to investigate relationships between sleep disorders and common brain diseases, followed by summary-data-based Mendelian randomization (SMR), heterogeneity in dependent instruments (HEIDI), and colocalization analyses integrating protein quantitative trait locus (pQTL) and expression quantitative trait locus (eQTL) data to prioritize genetically supported candidate genes. Compound-gene associations were subsequently evaluated, and selected clinically used compounds underwent exploratory molecular docking and molecular dynamics simulation. Two-step MR mediation analyses and MR phenome-wide association study (MR-PheWAS) were used to investigate potential mediating traits and broader phenotypic associations. Multi-omic genetic analyses prioritized six candidate genes—BCAN, HDGF, MEPE, PAM, PRR4, and IGLON5—with BCAN, HDGF, and MEPE showing the strongest genetic support. Compound prioritization retained four clinically used drugs associated with the candidate genes for structure-based assessment. Exploratory molecular docking yielded the most favorable predicted Vina score for the BCAN–danazol pair, and molecular dynamics simulation showed persistent local BCAN–danazol contacts despite substantial global conformational rearrangement of BCAN during the trajectory. Mediation analyses identified several risk factors, cerebrospinal fluid metabolites, and structural connectivity measures showing statistical evidence consistent with partial mediation of selected gene/protein–sleep disorder associations. MR-PheWAS further characterized broader phenotypic associations of the genetically supported genes. Integrating genetic and multi-omic evidence identified candidate molecular targets and compound-gene associations relevant to sleep disorders. These findings provide hypotheses for subsequent functional and pharmacological validation.
- Open Access
- 1 October 2025
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 58 (9) , 2060-2069
TET3 downregulation induces circadian disruption of BMAL1 through its DNA methylation-mediated repression in Alzheimer’s disease
Circadian disruptions appear at the presymptomatic stage of Alzheimer’s disease (AD) and may exacerbate mental dysfunction in AD. The downregulation of brain and muscle ARNT-like protein 1 (BMAL1), a key clock element for the maintenance of circadian rhythms, has been linked to epigenetic mechanisms. Our previous study revealed that the mRNA level of DNA demethylase ten–eleven translocation (Tet) 3 was reduced in the hippocampi of APPswe/PS1dE9 (APP/PS1) mice. However, the effects of TET3 on BMAL1 downregulation and circadian dysregulation in AD are still unclear. Our investigation first confirms that Tet3 mRNA and protein levels are decreased in both APP/PS1 mice and APPswe cells. In addition, decreased levels of 5hmC are observed in HT22 cells after TET3 knockdown, whereas TET3 overexpression reverses the reduction in 5hmC. Critically, we report that TET3 knockdown remethylates the Bmal1 promoter, thus downregulating BMAL1 expression in HT22 cells. In contrast, TET3 overexpression could upregulate BMAL1 by decreasing its methylation level. These results indicate that reduced TET3 is responsible for BMAL1 downregulation through decreased TET3 demethylation. Additionally, TET3 knockdown could lead to circadian disruption of BMAL1 in U2OS cells, whereas overexpression of TET3 alleviates the dysregulated biological rhythm in Aβ-treated U2OS cells. Our data suggest that TET3 plays a vital role in modulating the circadian rhythm at the epigenetic level through DNA demethylation.
- 1 October 2025
- Published by China Science Publishing & Media Ltd. in Acta Biochimica et Biophysica Sinica
- Vol. 58 (9) , 2060-2069
Open AccessTET3 downregulation induces circadian disruption of BMAL1 through its DNA methylation-mediated repression in Alzheimer’s disease
Circadian disruptions appear at the presymptomatic stage of Alzheimer’s disease (AD) and may exacerbate mental dysfunction in AD. The downregulation of brain and muscle ARNT-like protein 1 (BMAL1), a key clock element for the maintenance of circadian rhythms, has been linked to epigenetic mechanisms. Our previous study revealed that the mRNA level of DNA demethylase ten–eleven translocation (Tet) 3 was reduced in the hippocampi of APPswe/PS1dE9 (APP/PS1) mice. However, the effects of TET3 on BMAL1 downregulation and circadian dysregulation in AD are still unclear. Our investigation first confirms that Tet3 mRNA and protein levels are decreased in both APP/PS1 mice and APPswe cells. In addition, decreased levels of 5hmC are observed in HT22 cells after TET3 knockdown, whereas TET3 overexpression reverses the reduction in 5hmC. Critically, we report that TET3 knockdown remethylates the Bmal1 promoter, thus downregulating BMAL1 expression in HT22 cells. In contrast, TET3 overexpression could upregulate BMAL1 by decreasing its methylation level. These results indicate that reduced TET3 is responsible for BMAL1 downregulation through decreased TET3 demethylation. Additionally, TET3 knockdown could lead to circadian disruption of BMAL1 in U2OS cells, whereas overexpression of TET3 alleviates the dysregulated biological rhythm in Aβ-treated U2OS cells. Our data suggest that TET3 plays a vital role in modulating the circadian rhythm at the epigenetic level through DNA demethylation.
- Open Access
- 10 April 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (7) , e70546
IL ‐ 17A Induces Circadian Disruptions Through the Epigenetic Repression of BMAL1 in Mice With Alzheimer's Disease
Circadian disruptions and neuroinflammation impact nearly all people with Alzheimer's disease (AD), but their relationships with each other and the impact of their interaction on AD remain to be addressed. Here, we found that amyloid (A)‐β treatment downregulated brain and muscle aryl hydrocarbon receptor nuclear translocator‐like (BMAL) 1 through the hypermethylation of its promoter region in HT22 cells and that the inhibition of DNA methylation ameliorated circadian rhythm disorders and restored BMAL1 protein expression by reversing its hypermethylation in APPswe/PSEN1dE9 (APP/PS1) mice. Critically, increased levels of interleukin (IL)‐17A contributed to BMAL1 downregulation through the hypermethylation of its promoter region, thus leading to circadian disruptions in APP/PS1 mice. Moreover, we revealed that the mitogen‐activated protein kinase (MAPK) pathway was responsible for IL‐17A‐induced DNA methyltransferase (DNMT) 1 upregulation. Taken together, we elucidate a new mechanism connecting IL‐17A with altered DNA methylation of Bmal1 , which results in circadian disturbances in an AD mouse model.
- 10 April 2025
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 29 (7) , e70546
Open AccessIL ‐ 17A Induces Circadian Disruptions Through the Epigenetic Repression of BMAL1 in Mice With Alzheimer's Disease
Circadian disruptions and neuroinflammation impact nearly all people with Alzheimer's disease (AD), but their relationships with each other and the impact of their interaction on AD remain to be addressed. Here, we found that amyloid (A)‐β treatment downregulated brain and muscle aryl hydrocarbon receptor nuclear translocator‐like (BMAL) 1 through the hypermethylation of its promoter region in HT22 cells and that the inhibition of DNA methylation ameliorated circadian rhythm disorders and restored BMAL1 protein expression by reversing its hypermethylation in APPswe/PSEN1dE9 (APP/PS1) mice. Critically, increased levels of interleukin (IL)‐17A contributed to BMAL1 downregulation through the hypermethylation of its promoter region, thus leading to circadian disruptions in APP/PS1 mice. Moreover, we revealed that the mitogen‐activated protein kinase (MAPK) pathway was responsible for IL‐17A‐induced DNA methyltransferase (DNMT) 1 upregulation. Taken together, we elucidate a new mechanism connecting IL‐17A with altered DNA methylation of Bmal1 , which results in circadian disturbances in an AD mouse model.
- 14 March 2024
- Published by Elsevier in Physiology & Behavior
- Vol. 279, 114523
Melatonin attenuates fentanyl - induced behavioral sensitization and circadian rhythm disorders in mice
- 14 March 2024
- Published by Elsevier in Physiology & Behavior
- Vol. 279, 114523
Melatonin attenuates fentanyl - induced behavioral sensitization and circadian rhythm disorders in mice
- Open Access
- 11 March 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (4)
Berberine alleviates concanavalin A–induced autoimmune hepatitis in mice by modulating the gut microbiota
Background: Autoimmune hepatitis (AIH) is an immune-mediated liver disease of unknown etiology accompanied by intestinal dysbiosis and a damaged intestinal barrier. Berberine (BBR) is a traditional antibacterial medicine that has a variety of pharmacological properties. It has been reported that BBR alleviates AIH, but relevant mechanisms remain to be fully explored. Methods: BBR was orally administered at doses of 100 mg⋅kg−1⋅d−1 for 7 days to mice before concanavalin A–induced AIH model establishment. Histopathological, immunohistochemical, immunofluorescence, western blotting, ELISA, 16S rRNA analysis, flow cytometry, real-time quantitative PCR, and fecal microbiota transplantation studies were performed to ascertain BBR effects and mechanisms in AIH mice. Results: We found that liver necrosis and apoptosis were decreased upon BBR administration; the levels of serum transaminase, serum lipopolysaccharide, liver proinflammatory factors TNF-α, interferon-γ, IL-1β, and IL-17A, and the proportion of Th17 cells in spleen cells were all reduced, while the anti-inflammatory factor IL-10 and regulatory T cell proportions were increased. Moreover, BBR treatment increased beneficial and reduced harmful bacteria in the gut. BBR also strengthened ileal barrier function by increasing the expression of the tight junction proteins zonula occludens-1 and occludin, thereby blocking lipopolysaccharide translocation, preventing lipopolysaccharide/toll-like receptor 4 (TLR4)/ NF-κB pathway activation, and inhibiting inflammatory factor production in the liver. Fecal microbiota transplantation from BBR to model mice also showed that BBR potentially alleviated AIH by altering the gut microbiota. Conclusions: BBR alleviated concanavalin A–induced AIH by modulating the gut microbiota and related immune regulation. These results shed more light on potential BBR therapeutic strategies for AIH.
- 11 March 2024
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 8 (4)
Open AccessBerberine alleviates concanavalin A–induced autoimmune hepatitis in mice by modulating the gut microbiota
Background: Autoimmune hepatitis (AIH) is an immune-mediated liver disease of unknown etiology accompanied by intestinal dysbiosis and a damaged intestinal barrier. Berberine (BBR) is a traditional antibacterial medicine that has a variety of pharmacological properties. It has been reported that BBR alleviates AIH, but relevant mechanisms remain to be fully explored. Methods: BBR was orally administered at doses of 100 mg⋅kg−1⋅d−1 for 7 days to mice before concanavalin A–induced AIH model establishment. Histopathological, immunohistochemical, immunofluorescence, western blotting, ELISA, 16S rRNA analysis, flow cytometry, real-time quantitative PCR, and fecal microbiota transplantation studies were performed to ascertain BBR effects and mechanisms in AIH mice. Results: We found that liver necrosis and apoptosis were decreased upon BBR administration; the levels of serum transaminase, serum lipopolysaccharide, liver proinflammatory factors TNF-α, interferon-γ, IL-1β, and IL-17A, and the proportion of Th17 cells in spleen cells were all reduced, while the anti-inflammatory factor IL-10 and regulatory T cell proportions were increased. Moreover, BBR treatment increased beneficial and reduced harmful bacteria in the gut. BBR also strengthened ileal barrier function by increasing the expression of the tight junction proteins zonula occludens-1 and occludin, thereby blocking lipopolysaccharide translocation, preventing lipopolysaccharide/toll-like receptor 4 (TLR4)/ NF-κB pathway activation, and inhibiting inflammatory factor production in the liver. Fecal microbiota transplantation from BBR to model mice also showed that BBR potentially alleviated AIH by altering the gut microbiota. Conclusions: BBR alleviated concanavalin A–induced AIH by modulating the gut microbiota and related immune regulation. These results shed more light on potential BBR therapeutic strategies for AIH.
- Open Access
- 16 February 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (7) , e36970
Elucidation of the mechanism of Zhenbao pills for the treatment of spinal cord injury by network pharmacology and molecular docking: A review
To explore the mechanism of the Zhenbao pill (ZBP) in treating spinal cord injury (SCI). The TCMSP Database, HERB Database and literature search were used to screen the effective ingredients and targets of ZBP; SCI-related genes were searched in GeneCards, OMIM, PharmGkb, TTD and DrugBank databases; the potential targets of ZBP for treating SCI were predicted and Venn diagrams were drawn, and the “herb-ingredient-target” network was constructed by Cytoscape software. The PPI network was constructed by STRING software, and the core targets were screened by cytoNCA plug-in; GO enrichment and KEGG pathway analysis were performed on the predicted targets using the DAVID Platform, and visualized with the Microbiology Network Platform. The molecular docking between the key ingredients and the core target was carried out by AutoDockVina software. 391 active ingredients and 836 action targets were obtained from ZBP and there are 1557 SCI related genes in 5 disease databases. The top 5 active ingredients were Quercetin, Camptothecin, Kaempferol, Ethyl iso-allocholate, and Ethyl linoleate, and 5 core genes were SRC, CTNNB1, TP53, AKT1, and STAT3. GO enrichment analysis showed that the core targets were involved in 1206 biological processes, 120 cellular components and 160 molecular functions; KEGG enrichment analysis showed that the core targets involved 183 pathways, including PI3K-Akt signaling pathway and other signaling pathways. Molecular docking indicated that CTNNB1, SRC, TP53, AKT1 and STAT3 showed good binding ability with the active ingredients quercetin, kaempferol and ethyl isobutyric acid. ZBP improves SCI through multi-components, multi-targets and multi-pathways.
- 16 February 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (7) , e36970
Open AccessElucidation of the mechanism of Zhenbao pills for the treatment of spinal cord injury by network pharmacology and molecular docking: A review
To explore the mechanism of the Zhenbao pill (ZBP) in treating spinal cord injury (SCI). The TCMSP Database, HERB Database and literature search were used to screen the effective ingredients and targets of ZBP; SCI-related genes were searched in GeneCards, OMIM, PharmGkb, TTD and DrugBank databases; the potential targets of ZBP for treating SCI were predicted and Venn diagrams were drawn, and the “herb-ingredient-target” network was constructed by Cytoscape software. The PPI network was constructed by STRING software, and the core targets were screened by cytoNCA plug-in; GO enrichment and KEGG pathway analysis were performed on the predicted targets using the DAVID Platform, and visualized with the Microbiology Network Platform. The molecular docking between the key ingredients and the core target was carried out by AutoDockVina software. 391 active ingredients and 836 action targets were obtained from ZBP and there are 1557 SCI related genes in 5 disease databases. The top 5 active ingredients were Quercetin, Camptothecin, Kaempferol, Ethyl iso-allocholate, and Ethyl linoleate, and 5 core genes were SRC, CTNNB1, TP53, AKT1, and STAT3. GO enrichment analysis showed that the core targets were involved in 1206 biological processes, 120 cellular components and 160 molecular functions; KEGG enrichment analysis showed that the core targets involved 183 pathways, including PI3K-Akt signaling pathway and other signaling pathways. Molecular docking indicated that CTNNB1, SRC, TP53, AKT1 and STAT3 showed good binding ability with the active ingredients quercetin, kaempferol and ethyl isobutyric acid. ZBP improves SCI through multi-components, multi-targets and multi-pathways.
- Open Access
- 9 June 2023
- Published by Springer Nature in Research Square
Noninvasive deep brain stimulation via temporal interference electric fields enhanced motor performance of mice and its neuroplasticity mechanisms
A noninvasive deep brain stimulation via temporal interference (TI) electric fields is a novel neuromodulation technology, but few advances about TI stimulation effectiveness and mechanisms have been reported. In the present study, TI stimulation was proved to stimulating noninvasively primary motor cortex (M1) of mice, and 7 days TI stimulation with an envelope frequency of 20 Hz (∆f = 20 Hz), instead of an envelope frequency of 10 Hz (∆f = 10 Hz), could obviously improve mice motor performance. The mechanism of action may be related to enhancing the strength of synaptic connections, improving synaptic transmission efficiency, increasing dendritic spine density, promoting neurotransmitter release, and increasing the expression and activity of synapse-related proteins, such as brain-derived neurotrophic factor (BDNF), postsynaptic density protein-95 (PSD-95), and glutamate receptor protein. Furthermore, the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway and its upstream BDNF play an important role in the enhancement of locomotor performance in mice by TI stimulation. To our knowledge, it is the first report about TI stimulation promoting multiple motor performances and describing its mechanisms. TI stimulation might serve as a novel promising approach to enhance motor performance and treat dysfunction in deep brain regions.
- 9 June 2023
- Published by Springer Nature in Research Square
Open AccessNoninvasive deep brain stimulation via temporal interference electric fields enhanced motor performance of mice and its neuroplasticity mechanisms
A noninvasive deep brain stimulation via temporal interference (TI) electric fields is a novel neuromodulation technology, but few advances about TI stimulation effectiveness and mechanisms have been reported. In the present study, TI stimulation was proved to stimulating noninvasively primary motor cortex (M1) of mice, and 7 days TI stimulation with an envelope frequency of 20 Hz (∆f = 20 Hz), instead of an envelope frequency of 10 Hz (∆f = 10 Hz), could obviously improve mice motor performance. The mechanism of action may be related to enhancing the strength of synaptic connections, improving synaptic transmission efficiency, increasing dendritic spine density, promoting neurotransmitter release, and increasing the expression and activity of synapse-related proteins, such as brain-derived neurotrophic factor (BDNF), postsynaptic density protein-95 (PSD-95), and glutamate receptor protein. Furthermore, the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway and its upstream BDNF play an important role in the enhancement of locomotor performance in mice by TI stimulation. To our knowledge, it is the first report about TI stimulation promoting multiple motor performances and describing its mechanisms. TI stimulation might serve as a novel promising approach to enhance motor performance and treat dysfunction in deep brain regions.
- Open Access
- 9 May 2022
- Published by Springer Nature in Research Square
Integrated Analysis of Genes Related to Alzheimer’s Disease Pathogenesis Using Gene Co-expression Networks
Background: This study aims to identify key molecular targets in Alzheimer’s disease (AD) occurrence and progression.Methods: GSE5281 was obtained by screening and collection of the GEO database and denoted as set 1. Differential analysis was carried out on AD samples and healthy samples in set 1. Hippocampal tissues which were extracted from APP/PS1 double transgenic mice were used to measure the syntaxin 17 (STX17) gene and protein expression. Set 1 samples was divided into the STX17 high expression group and the low expression group and denoted as set 2. Differential analysis was carried out on set 2. The hippocampal sample expression matrix in GSE48350 was named as set 3 for weighted gene co-expression network analysis (WGCNA). GSE33000 was used to construct the Least absolute shrinkage and selection operator (LASSO) model for analysis and validation. Results: 6151 differentially expressed genes (DEGs) were obtained in set 1. STX17 has significantly low expression in the hippocampal tissues of AD mice. 3651 DEGs were obtained from set 2. 2658 common DEGs were obtained in the overlap of the two sets. 22 co-expression modules were obtained from set 3. 401 genes were ultimately obtained from the overlap between genes in the WGCNA significance module and the common DEGs in the two sets and Cytoscape was used for further visualization analysis to obtain the PPI networks of 18 crucial genes. LASSO model construction and fitting was carried out to obtain seven genes common to AD and STX17 (AMPH, GAD2, GAP43, REPS2, SGIP1, STXBP1, SYN2).Conclusion: Bioinformatics analysis was used to examine the intrinsic mechanisms of AD pathogenesis and determine the important role of STX17 in AD progression. Integrated analysis was used to obtain crucial molecular targets common to AD and STX17, which provides new ideas for future AD mechanistic studies and treatment.
- 9 May 2022
- Published by Springer Nature in Research Square
Open AccessIntegrated Analysis of Genes Related to Alzheimer’s Disease Pathogenesis Using Gene Co-expression Networks
Background: This study aims to identify key molecular targets in Alzheimer’s disease (AD) occurrence and progression.Methods: GSE5281 was obtained by screening and collection of the GEO database and denoted as set 1. Differential analysis was carried out on AD samples and healthy samples in set 1. Hippocampal tissues which were extracted from APP/PS1 double transgenic mice were used to measure the syntaxin 17 (STX17) gene and protein expression. Set 1 samples was divided into the STX17 high expression group and the low expression group and denoted as set 2. Differential analysis was carried out on set 2. The hippocampal sample expression matrix in GSE48350 was named as set 3 for weighted gene co-expression network analysis (WGCNA). GSE33000 was used to construct the Least absolute shrinkage and selection operator (LASSO) model for analysis and validation. Results: 6151 differentially expressed genes (DEGs) were obtained in set 1. STX17 has significantly low expression in the hippocampal tissues of AD mice. 3651 DEGs were obtained from set 2. 2658 common DEGs were obtained in the overlap of the two sets. 22 co-expression modules were obtained from set 3. 401 genes were ultimately obtained from the overlap between genes in the WGCNA significance module and the common DEGs in the two sets and Cytoscape was used for further visualization analysis to obtain the PPI networks of 18 crucial genes. LASSO model construction and fitting was carried out to obtain seven genes common to AD and STX17 (AMPH, GAD2, GAP43, REPS2, SGIP1, STXBP1, SYN2).Conclusion: Bioinformatics analysis was used to examine the intrinsic mechanisms of AD pathogenesis and determine the important role of STX17 in AD progression. Integrated analysis was used to obtain crucial molecular targets common to AD and STX17, which provides new ideas for future AD mechanistic studies and treatment.